SPHERA FUNDS MANAGEMENT LTD. Q3 2023 significant ownership

Add to watchlist

SPHERA FUNDS MANAGEMENT LTD. is required to file a 13D/G report to the SEC when the ownership of a company's total stock issue exceeds 5%.

SPHERA FUNDS MANAGEMENT LTD. Q3 2023 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Cyclacel Pharmaceuticals, Inc.February 06, 2023250,0002.0%
Altimmune, Inc.February 14, 20221,244,2413.1%
Allot Ltd.February 16, 20211,129,0543.2%
Larimar Therapeutics, Inc.February 16, 2021? ?
Neos Therapeutics, Inc.February 16, 2021? ?
Orgenesis Inc.February 16, 2021525,2160.0%
Sio Gene Therapies Inc.February 16, 2021? ?
X4 Pharmaceuticals, IncFebruary 16, 2021250,0000.0%
Axovant Gene Therapies Ltd.February 25, 20202,931,0178.0%
Axovant Gene Therapies Ltd.February 11, 2020398,5401.8%
Evoke Pharma IncSold outFebruary 11, 202000.0%
VistaGen Therapeutics, Inc.February 11, 20201,314,9492.7%
ZAFGEN, INC.February 11, 20202,836,3677.6%
Aldeyra Therapeutics, Inc.February 13, 201914.7%
Eiger BioPharmaceuticals, Inc.February 13, 201987,1890.5%
Viking Therapeutics, Inc.February 13, 2019770,7271.1%
MARINUS PHARMACEUTICALS INCSold outFebruary 13, 201800.0%
Achaogen IncFebruary 13, 2017514,3421.9%
Ellomay Capital Ltd.February 26, 2015454,4904.2%

Compare quarters

Export SPHERA FUNDS MANAGEMENT LTD.'s holdings

CSVXLS